Update on Kidney Injury Biomarkers

Overview

Novel biomarkers should be combined with functional markers (serum creatinine, cystatin C) and clinical assessment to enable earlier AKI detection, improve risk stratification, and guide management decisions. 1

The 2020 Acute Disease Quality Initiative (ADQI) consensus conference established 11 recommendations for integrating novel biomarkers into clinical practice, representing the most comprehensive guideline framework available. 1

Key Biomarker Categories

Novel AKI biomarkers fall into three mechanistic categories that provide complementary information: 1

Stress Markers

TIMP-2 × IGFBP7 (cell cycle arrest markers): Indicate cellular stress before structural damage occurs 1
Released during early tubular stress that may resolve or progress to injury 1

Damage Markers

NGAL (neutrophil gelatinase-associated lipocalin): Released from distal tubule after injury 1, 2
KIM-1 (kidney injury molecule-1): Proximal tubule injury marker 3, 2, 4
L-FABP (liver-type fatty acid-binding protein): Proximal tubule damage indicator 2, 4
IL-18: Inflammatory marker reflecting tubular injury 4

Functional Markers

Cystatin C: More accurate GFR estimation than creatinine alone, less affected by muscle mass 1, 4
Proenkephalin A (PENK): Freely filtered marker of glomerular function 1, 5, 4

Clinical Applications

1. Risk Assessment and Early Detection

Use TIMP-2 × IGFBP7 for risk stratification in critically ill patients, with a cutoff of 0.3 (ng/mL)²/1000 to identify high-risk individuals. 1

Patients with urinary TIMP-2 × IGFBP7 <0.3 (ng/mL)²/1000 have low risk of progressing to severe AKI, even with oliguria 1
Values >0.3 (ng/mL)²/1000 predict death or need for kidney replacement therapy (HR 2.16,95% CI 1.32-3.53) 1
Biomarkers detect injury 24-48 hours before serum creatinine rises 1, 3

2. Expanded AKI Diagnostic Criteria

The ADQI consensus proposes subdividing KDIGO Stage 1 AKI into three substages based on biomarker positivity: 1

Stage 1S: Biomarker positive WITHOUT creatinine/urine output changes (subclinical AKI)
Stage 1A: Creatinine/urine output changes WITH biomarker negative
Stage 1B: Creatinine/urine output changes WITH biomarker positive

This reclassification matters because patients with elevated damage biomarkers (like NGAL) without creatinine elevation have 4-fold increased risk of developing full AKI and worse outcomes compared to biomarker-negative patients. 1

3. Guiding Nephrotoxic Drug Dosing

Combine cystatin C with creatinine for more accurate GFR estimation when dosing nephrotoxic medications. 1

CKD-EPI equations using both creatinine and cystatin C improve vancomycin dosing accuracy by 22% compared to creatinine alone 1
For life-saving nephrotoxic drugs, serial monitoring of both functional and damage biomarkers helps optimize dosing and duration 1

4. Predicting Recovery and RRT Liberation

Urinary NGAL shows fair-to-good predictive performance (AUC 0.766-0.801) for successful RRT discontinuation in the short term. 5

Higher cystatin C at RRT discontinuation independently predicts chronic dialysis dependence 1
TIMP-2 × IGFBP7 >0.3 (ng/mL)²/1000 at ICU discharge associates with death or continued RRT need 1
However, biomarker predictive value for 1-year mortality remains modest (AUROC 0.61-0.70) 1

5. Process of Care Optimization

Negative biomarker results have clinical utility by ruling out high-risk AKI, potentially avoiding unnecessary interventions. 1

Oliguria with TIMP-2 × IGFBP7 <0.3 indicates low progression risk 1
Serial biomarker testing should be performed when patient risk profile changes 1

Practical Implementation Algorithm

For High-Risk Patients (ICU, post-cardiac surgery, sepsis):

Baseline assessment: Measure TIMP-2 × IGFBP7 and/or NGAL at admission or pre-procedure 1
Risk stratification:
- TIMP-2 × IGFBP7 ≥0.3 (ng/mL)²/1000 → High risk, implement preventive bundle 1
- TIMP-2 × IGFBP7 <0.3 (ng/mL)²/1000 → Standard monitoring 1
Serial monitoring: Repeat biomarkers every 12-24 hours in high-risk patients or when clinical status changes 1
Combine with functional markers: Use cystatin C alongside creatinine for more accurate GFR assessment 1
Interpret in context: Positive damage biomarkers (NGAL, KIM-1) without creatinine rise still indicate injury requiring intervention 1

For Nephrotoxic Drug Monitoring:

Calculate eGFR using both creatinine and cystatin C (CKD-EPI equation) 1
Monitor damage biomarkers (NGAL, KIM-1) serially during treatment 1
Adjust dosing if damage biomarkers rise even without creatinine changes 1

Critical Caveats and Limitations

Current Knowledge Gaps 1

Optimal cutoff values vary across studies and populations, limiting standardization 3, 5
Cost-effectiveness of routine biomarker testing remains unproven 1
Single vs. serial measurements: Unclear which strategy provides optimal predictive value 1
Combination strategies: Best combinations of biomarkers not yet established 1

Common Pitfalls to Avoid

Don't rely on biomarkers alone: Always integrate with clinical assessment and traditional markers 1
Context matters: Biomarker performance varies by clinical setting (cardiac surgery vs. sepsis vs. nephrotoxin exposure) 3, 6
Timing is critical: Biomarkers have different temporal patterns; TIMP-2 × IGFBP7 peaks early (4-12 hours), while NGAL peaks later (12-24 hours) 2
Subclinical AKI requires action: Elevated damage biomarkers without creatinine rise (Stage 1S) still predict worse outcomes and warrant intervention 1

Validation Status

TIMP-2 × IGFBP7 and NGAL have FDA clearance and strongest validation 3, 7
Other biomarkers (KIM-1, L-FABP, IL-18, cystatin C) show promise but require further validation in diverse populations 3, 6, 2
Emerging candidates (microRNAs, suPAR, CHI3L1) remain investigational 4

Future Directions

The ADQI consensus identifies 14 research priorities, with key areas including: 1

Prospective validation of biomarker-guided interventions to prevent AKI progression
Determining whether biomarker changes without creatinine elevation warrant treatment
Evaluating biomarker combinations for predicting RRT need and optimal timing
Assessing long-term outcomes (CKD progression) using biomarker-based risk stratification
Integration with artificial intelligence and electronic health records for real-time decision support 8

What are the latest renal biomarkers for early detection and risk stratification of acute kidney injury, and how should they be used?

Help us tailor your experience